Cosmetic cross-reference Noindex: medium evidence

Pentanal

CAS 110-62-3

Pentanal (CAS 110-62-3) is a pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
1
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Pentanal
CAS Number
110-62-3
UNII
B975S3014W
InChIKey
HGBOYTHUEUWSSQ-UHFFFAOYSA-N
ChEMBL ID
CHEMBL18602
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 1 bioactivity row

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 51533.13333333333 nM 3 -
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Pentanal used for in pharmaceutical contexts?

Pentanal (CAS 110-62-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Pentanal?

No adverse-event association or SIDER side-effect rows are rendered for Pentanal in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Pentanal also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Valeraldehyde with EU status "permitted".

What clinical phase is Pentanal in?

No phase 1-4 clinical development badge is rendered for Pentanal because the matched compound identifier rows do not contain a max-phase value.